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NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY: A 
SENSITIVITY ANALYSIS ON THE ECOG STATUS
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OBJECTIVES: Novel combination therapies can improve survival compared with 
chemotherapy alone in patients with advanced NSCLC. However, acceptable tolera-         
bility is also important as it affects clinical outcomes, quality of life, and overall cancer 
treatment costs. This analysis assesses direct medical costs for the management of 
grade 3/4 adverse events (AEs) associated with two non-chemotherapies for ﬁrst-line 
treatment of NSCLC consisting of either Bevacizumab (BEV) plus chemotherapy (CT) 
or Cetuximab (C) plus cisplatin/vinorelbine (CV). METHODS: Information on AE 
proﬁles were retrieved from the AVAiL study (7.5 mg/kg, Reck et al. 2009) and the        
E4599 study (15 mg/kg, Sandler et al. 2006) for BEV       CT and from the FLEX study 
(Pirker et al. 2009) for CCV. To account for the inclusion of ECOG 2 patients in 
FLEX (which were excluded in AVAiL and E4599), incidences of febrile neutropenia, 
non-febrile neutropenia and leukopenia in FLEX were decreased by up to 30% based 
on expert suggestion to improve study comparability. Information on standard treat-
ment patterns of the different AEs was collected through a systematic literature search 
and complemented by data provided by two German oncologists. These resource use 
items were assigned unit costs (charges) applicable to Germany. RESULTS: When 
unadjusted incidences of all AEs reported in AVAiL, E4599, and FLEX are used, 
resulting overall per-patient treatment costs related to the two BEVCT studies are 
substantially lower those related to CCV (a1092 and a464 versus a2287). Sensitivity 
analyses provide evidence that overall AE costs remain lower for AVAiL and E4599 
even when incidences for selected AEs affected by cetuximab therapy are reduced by 
10%, 20%, and 30% (a2151, a2015, and a1879, respectively). CONCLUSIONS: 
BEVCT shows better tolerability linked with lower AE treatment costs when com-
pared to CCV. These favorable outcomes for BEVCT were maintained when AE 
frequencies for CCV were adjusted for ECOG status.
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OBJECTIVES: Novel combination therapies can improve survival as compared to         
chemotherapy alone in patients with advanced NSCLC. Essential is also that these          
new therapies have acceptable tolerability proﬁles. Furthermore, toxicities can result 
in potentially high additional treatment costs. This analysis therefore aims to explore 
overall costs of adverse events (AEs) associated with two new biologics in ﬁrst-line 
NSCLC consisting of either Bevacizumab (BEV) combined with chemotherapy (CT) 
or Cetuximab (C) combined with cisplatin  vinorelbine (CV). METHODS: All pub-
lished AEs and their incidences as reported in the AVAiL study (7.5 mg/kg, Reck et    
al. 2009) and the E4599 study (15 mg/kg, Sandler et al. 2006) were considered for         
BEVCT, whereas AE data for CCV was taken from the FLEX study (Pirker et al. 
2009). A systematic literature search was performed to collect published information 
on standard treatment patterns and costs of AEs. To complement and further sub-
stantiate these results, two oncologists in Germany were interviewed to obtain 
 additional information on medical resource utilization for the AEs considered. These 
resource use items were then assigned unit costs (charges) reﬂective of the German 
health care system. A spreadsheet model was used to calculate total average per-patient 
AE costs for the two compared therapy regimens. RESULTS: Our analysis shows 
substantially lower overall per-patient treatment costs for the grade 3/4 AE proﬁles 
speciﬁed in both BEV NSCLC trials (AVAiL and E4599) than for all severe AEs 
observed in the FLEX trial (a1092 and a464 versus a2287). The differences favouring 
BEVCT are mainly due to lower incidences of febrile neutropenia, leukopenia, neu-
tropenia, sepsis, and anaemia than observed for a CCV regimen. CONCLUSIONS: 
BEVCT shows better tolerability and lower AE treatment costs as compared to 
CCV. Coupled with its favorable effectiveness, BEVCT should be considered as 
therapy of choice for patients with advanced NSCLC.
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OBJECTIVES: To estimate the average lifetime cost of care for patients with colorectal 
cancer in Ireland, from the perspective of the health care payer (HSE). METHODS: 
A decision tree model was developed in Microsoft Excel. Treatment pathways were 
constructed for each stage of colon cancer (CC) and rectal cancer (RC) from guidelines 
and expert clinical opinion. Healthcare resource use associated with diagnosis, treat-
ment and follow-up were obtained from the National Cancer Registry (n  1,498; 
36% RC and 64% CC; 2004–2005), and two local hospital databases (n  155 and 
142; 2007). Unit costs for hospitalisation, procedures, laboratory tests and radiother-
apy were derived from DRG costs, hospital ﬁnance departments, clinical opinion and 
literature review. Chemotherapy costs were estimated from local hospital protocols, 
pharmacy department and clinical opinion. Future costs of follow-up were discounted 
at 4% over 5 years. Uncertainty was explored using one-way sensitivity analysis. 
RESULTS: Average lifetime costs per patient were higher for RC (Stage I a24,089; 
Stage II a40,950; Stage III a49,987; Stage IV a45,237) than CC (Stage I a23,462; Stage 
II a35,059; Stage III a48,186; Stage IV a31,774). Cost estimates were most sensitive 
to recurrence rates and prescribing of the biologic agents bevacizumab and cetuximab. 
CONCLUSIONS: This study demonstrates how costs of managing cancer can be 
estimated using existing data from national and local databases. The ﬁndings illustrate 
the major impact that the new biologic agents have on the cost of cancer care. They 
also highlight the potential to reduce health care resource utilisation by implementing 
strategies to detect colorectal cancer at earlier stages.
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OBJECTIVES: A cross-sectional retrospective, prevalence-based study was designed 
to measure costs and QoL associated with MM management at different disease phases 
in a societal perspective. METHODS: A snapshot questionnaire was administered to 
236 subjects in 5 Italian hematological centers. Health-related QoL was measured 
using the EORTC QLQ-C30 and its MM speciﬁc module MY24, administered to 199 
patients at enrolment). Four disease-phases were considered in a distribution that 
reﬂects real clinical practice: asymptomatic, “watch-and-wait” (16%); symptomatic, 
receiving an autotransplant (12%); symptomatic, receiving drugs (45%); and plateau/
remission (including best supportive care) (27%). Costs were identiﬁed over 1 year 
of disease management with regard to: drugs, visits, laboratory tests, hospital admis-
sions, support devices, home assistance, travel, and reduced productivity of patients 
and caregivers. Costs for working days lost were derived according to the human 
capital method. RESULTS: The average costs per subject per year were a20,695 while 
direct health care costs were a16,717 and direct non-health care costs were a447; 
indirect costs (productivity loss) were a3,531 per subject per year. The average direct 
health care costs per subject per year were: a660; a53,020; a18,892; a6,319 for 
asymptomatic, autotransplanted, receiving drugs and plateau/remission respectively. 
The groups with the highest resource utilization were the autotransplanted and those 
receiving drugs. Regarding QoL, our sample of 199 patients recorded a 60.93 Global 
Health Score in QLQ-C30 (asymptomatic: 71.05; autotransplanted: 57.41; receiving 
drugs: 49.25; Plateau/remission: 72.02). CONCLUSIONS: The main resource utiliza-
tion comes from direct medical costs. MM treatment strategy has changed dramati-
cally in the past years. In particular, transplant and pharmacological treatments 
represent the most relevant costs, although counterbalanced by the highly increased 
clinical outcomes reported in literature (Kumar,Blood,2007). The QoL analysis 
showed the impact of maintaining patients in the plateau/remission phase, which 
ensures that their QoL and particularly the global health score is comparable with 
asymptomatic.
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OBJECTIVES: With 16,005 new cases and 5,406 related deaths in 2005, France is 
particularly concerned by Head and Neck (H&N) cancers. In addition to tobacco and 
alcohol, Human Papillomavirus (HPV) has been reported as a risk factor for H&N 
cancers. The literature on the burden of these cancers in Europe is scarce. This study 
was performed to assess the medical and economical burden of hospitalisations for 
H&N cancers in France. METHODS: The French national hospital database (PMSI), 
in which admissions to public and private hospitals are recorded, was retrospectively 
analysed to assess the annual number of patients hospitalised for H&N cancers and 
associated hospital costs from the health care payer perspective. ICD-10 codes (16 
codes classiﬁed as oral cavity, pharynx, salivary glands, larynx) were used to extract 
admissions for these cancers. Hospital stays, chemotherapy and radiotherapy sessions 
were extracted to assess patients’ management. Costs of admissions were obtained 
from French ofﬁcial tariffs. RESULTS: In 2007, there were 35,069 patients hospital-
ised for H&N cancers, of whom 81% were men, corresponding to 60,200 hospital 
stays and 242,935 sessions of chemo- or radio-therapy. Pharynx cancer was the most 
frequent (49% of patients), followed by oral cavity cancer (37% of patients). The 
peak of frequency was observed in the 55–59 years age group. Patients were mainly 
treated in medicine (47%) and surgery (23%) units. Mean annual cost per patient 
ranged from a3,285 to a8,924, leading to a total hospital cost of a275 millions in 
2007. CONCLUSIONS: The hospital burden of H&N cancers is considerable. Fur-
thermore, these costs are underestimated since radiotherapy sessions performed in 
the private sector as well as expensive drugs were not available from the PMSI. The 
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proportion of HPV-related cancers remains to be established site by site and further 
research is needed to assess outpatient and indirect costs linked to these cancers.
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OBJECTIVES: This incidence-based cost-of-illness analysis aims to quantify the costs 
associated with female breast cancer in Flanders for the year prior to diagnosis and 
for each of the ﬁve years following diagnosis. METHODS: A bottom-up analysis from 
the societal perspective included direct health care costs and indirect costs of produc-
tivity loss due to morbidity and premature mortality. A retrospective case-control 
study design compared total costs of breast cancer patients with costs of an equivalent 
standardised population with a view to calculating the additional costs that can be 
attributed to breast cancer. The sample was made up of women who had undergone 
surgical treatment for breast cancer and who were afﬁliated with the Christian Health 
Insurance Funds. Resource utilisation data were derived from national publications, 
the Christian Health Insurance Funds and statistical institutes. RESULTS: The sample 
consisted of 20,439 breast cancer patients. Total average costs of breast cancer 
amounted to a107,456 per patient over 6 years. Total costs consisted of productivity 
loss costs (89% of costs) and health care costs (11% of costs). Health care costs did 
not vary with age at diagnosis. Health care costs of breast cancer patients converged 
with those of the general population at ﬁve years following diagnosis. Patients with 
advanced breast cancer stadia had higher health care costs. CONCLUSIONS: To 
reduce costs associated with breast cancer, attention needs to be focused on decreasing 
the productivity loss from breast cancer. The implementation of new techniques to 
prevent, diagnose, and treat breast cancer not only impact direct health care costs, 
but may also inﬂuence indirect costs of productivity loss.
PCN52
COSTS OF ADVANCED GASTRIC CANCER (AGC) IN BRAZIL FROM THE 
PUBLIC PAYER PERSPECTIVE
Clark O1, Santos EA2, Saggia MG2
1Evidencias Medicas, Campinas, Sao Paulo, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil
OBJECTIVES: In Brazil, 140 million citizens (^80% of the population) depend on the 
public health care system. Advanced gastric cancer (AGC) is the second most frequent 
cause of death in Brazil: 10,645 per year. This disease appears among the most costly 
cancers to treat. Objective was to identify the medical resource usage (MRU) to treat 
AGC and estimate the associated costs in the public health care sector in Brazil. 
METHODS: A questionnaire was developed to identify the medical resource usage 
(MRU) of managing AGC in the public health care system. The questionnaire was 
applied to 20 oncologists and 20 nurses in a structured interview. MRU data were 
extracted according to the following stages: 1) diagnosis and staging; 2) 1st line treat-
ment, 3) 2nd line treatment; 4) best supportive care (BSC); and 5) terminal care. Then, 
modiﬁed Delphi panels were conducted in the 5 largest cities of Brazil to reach a con-
sensus on the base-case value and on the possible ranges of each resource used. 
Financial values were translated into USD based on the exchange rate of R$2.40  
US$1.0. RESULTS: The mostly used diagnostic procedures were upper digestive 
endoscopy, abdominal computed axial tomography (CAT) and thoracic radiography. 
For 1st line treatment, 5FU-based chemo was the ﬁrst choice of 50% of the oncologists 
interviewed, either given in combination with cisplatin (22%), etoposide (17%) or 
cisplatin plus doxorubicin (11%). Most commonly used resources in BSC/terminal 
care were blood analysis and anti-algic radiation. The mean cost per patient were: 
diagnostic and staging: R$451 (US$188); 1st line treatment: R$4565 (US$1902); 2nd 
line treatment: R$2740 (US$1142); BSC: R$883 (US$368); and terminal care: R$416 
(US$173). The total mean cost per patient were therefore R$9056 (US$3773) of which 
chemotherapy drugs represented 37%. CONCLUSIONS: Findings suggest that the 
total mean cost of treating AGC per patient in the public sector in Brazil is R$9056 
(US$3773).
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OBJECTIVES: Gastric cancer is the second most frequent cause of cancer death 
worldwide. Approximately 22,000 new cases are expected in Brazil annually. Our aim 
was to estimate the cost per disease stage of advanced gastric cancer in Brazil in the 
private health care sector. METHODS: A questionnaire was developed to identify the 
medical resource usage (MRU) of managing gastric cancer in the private health care 
system. The questionnaire was applied in a structured interview to 40 experts (20 
oncologists and 20 nurses) who represented different Brazilian regions. MRU data 
were extracted according to the following stages: 1) diagnosis and staging; 2) 1st line 
treatment; 3) 2nd line treatment; 4) best supportive care (BSC), and v) terminal care. 
Later, a modiﬁed Delphi panel was conducted to reach a consensus on the base-case 
value and on possible ranges for each resource identiﬁed. A micro-costing technique 
was then applied to calculate costs. Financial values were translated into USD based 
on the exchange rate of R$2.40  US$1.0. RESULTS: The most used diagnostic pro-
cedures were upper digestive endoscopy, abdominal computed axial tomography 
(CAT) and thoracic radiography. 5FU/capecitabine-based chemo was the oncologists’ 
ﬁrst choice for both 1st and 2nd line treatment (48% and 42%, respectively). Most 
commonly used resources in the BSC/ terminal care stages were medical visits and 
blood analysis. The mean cost per patient were: diagnostic and staging: R$1,283 (US$ 
535); 1st line treatment: R$ 0.502 (US$12,710); 2nd line treatment: R$ 6,406 
(US$2,670); BSC; R$6,833 (US$2,847); and terminal care: R$743 (US$310). The total 
mean cost per patient were R$45,768 (US$19,070), of which chemotherapy drugs 
represented 66%. CONCLUSIONS: The ﬁndings indicate that the most expensive 
stage in treating advanced gastric cancer in the private sector in Brazil is the 1st line 
treatment. Further studies are recommended to explore the results.
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OBJECTIVES: To examine the patient characteristics, comorbidities, and medication 
usage of subjects diagnosed with mGC. METHODS: Subjects in the Marketscan 
Commercial Claims and Encounter Database (July 1, 2003–June 30, 2008) were 
included for analysis if they received a diagnosis of mestastasis based on ICD-9 codes 
on or after the ﬁrst occurrence of GC, had no claims for other secondary metastases 
in the 6 months prior to the initial mGC claim, and had continuous insurance coverage 
from 6 months prior through at least one month post the initial diagnoses of mGC. 
Health care costs and resource utilization (HRU) are described from the date of initial 
mGC diagnosis through end of data collection due to patient drop out or end of the 
data collection period (e.g. post-period). Study data are shown as summary (or descrip-
tive) statistics. RESULTS: A total of 2058 subjects with mGC were included in the 
analysis. At mGC diagnosis, the median age was 58 years (25th /75th percentile: 31 
and 62 years respectively) and 60% were male. The mean length of follow-up after 
mGC was 2.6 years (SD: 1.3 years). The most common comorbidities at the time of 
mGC diagnosis were cardiovascular disease (48%), hypertension (29%), and diabetes 
(16%). Sixty-ﬁve percent of mGC subjects received outpatient chemotherapy in the 
post-period. Mean monthly medical costs were $5080 in the post-period, which con-
sisted of 46% inpatient costs, 40% outpatient costs, and 14% outpatient chemother-
apy costs. CONCLUSIONS: One-third of mGC patients were not treated with 
outpatient oncolytics. Outpatient chemotherapy costs constituted a small portion of 
the total cost of mGC.
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OBJECTIVES: Sunitinib and sorafenib, the multikinase inhibitors, launched into the 
Czech market in the middle of 2006 as a second-line treatment of metastatic renal cell 
carcinoma (mRCC) and were not yet economically evaluated in real clinical practice. 
The aim was to assess direct medical costs in mRCC patients treated in comprehensive 
cancer centre from a health care payer perspective. METHODS: Between May 2006 
and May 2009 31 mRCC patients were treated with sorafenib and/or sunitinib after 
previous cytokine therapy failure (mean age 52 years; 23 men). The progression of 
disease and costs (including concomitant medication, examination, check-ups, hospi-
talization) were assessed each two-months of therapy. Cost of cycle to progression, 
cost of cycle after progression and the structure of costs were determined. (1a  
26.8CZK) RESULTS: Seventeen patients started therapy with sunitinib, 8 of which         
were converted to sorafenib after progression. 3 patients ﬁnished sunitinib therapy 
due to adverse events (AE). Fourteen patients started with sorafenib therapy, 2 of 
which were converted to sunitinib due to AE, other 2 patients were converted to 
sunitinib after progression. The main AE were skin toxicity, oedema, arthralgia and 
other pain. The dose was reduced in 10 patients due to AE. Median number of two-
month progression free cycles was 4; mean cost of one cycle was a7546. Cost of 
medication formed 95.4% (sunitinibsorafenib 94.3%), investigations and check-ups 
4.42% and hospitalizations 0.18% of total costs. Median two-month cycles after 
progression was 2 with mean cost a4840. Sunitinib and sorafenib formed 90.5%, 
investigations and check-ups 6.2%; and hospitalizations 0.8% of total costs; 9 patients 
died. CONCLUSIONS: The analysis of direct medical costs in patients with mRCC 
proved high costs concerned with multikinase inhibitors´ therapy. Since data on the 
economic burden of oncology treatment in the Czech Republic are limited it is essential 
to start with cost-of-illness studies to enable pharmacoeconomic analyses for drug 
reimbursement.
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OBJECTIVES: Renal cell carcinoma (RCC) accounts for three peercent deaths in 
Finland. However, information on treatment modalities and the cost of treatment in 
different hospitals is scarce. The aim of the study was to clarify the current situation 
